Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04622319
Title A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Daiichi Sankyo, Inc.
Indications

Her2-receptor positive breast cancer

Therapies

Trastuzumab deruxtecan

Ado-trastuzumab emtansine

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.